摘要:
The present invention relates to the discovery of novel genes encoded by the interleukin-1 locus. The IL-1L1 gene is located in the interval between the IL-1Beta and IL-1 receptor antagonist encoding genes and encodes a polypeptide which is homologous to both IL-1 agonist and IL-1 antagonist proteins. Therapeutics, diagnostics and screening assays based on these molecules are also disclosed.
摘要:
The present invention is directed to novel polypeptides having homology to the IL-1-like family of proteins and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention, and methods for producing the polypeptides of the present invention.
摘要:
A method of producing circularly-permuted proteins (permuteins) by scanning permutagenesis comprises making and inserting a series of circularly-permuted genes into a display vector, expressing these genes such that the gene products are localized to the surface of the display vector, generating a library of display vectors presenting the permuted protein, affinity-selecting the display vectors with a target protein that can bind the permuted protein, isolating and analyzing clones of selected display vectors to identify the circularly-permuted protein. The invention further discloses methods of expressing and uses of permuteins.
摘要:
Disclosed are a polypeptide comprising the amino acid sequence of SEQ ID NO:5 or an amino acid sequence which has a homology of at least 75% with respect to the amino acid sequence of SEQ ID NO:5 and contains the amino acid sequence of SEQ ID NO:7 as an internal partial amino acid sequence; a DNA comprising either a nucleotide sequence which has the nucleotide sequence of SEQ ID NO:4, a nucleotide sequence which has a homology of at least 75% with respect to the nucleotide sequence of SEQ ID NO:4 and contains the nucleotide sequence of SEQ ID NO:8 at the 5'-terminus, or a complementary nucleotide sequence thereunto; an antibody which immunologically reacts with the polypeptide; and a method for detecting the polypeptide.
摘要翻译:公开了包含SEQ ID NO:5的氨基酸序列或与SEQ ID NO:5的氨基酸序列具有至少75%同源性并且含有SEQ ID NO:5的氨基酸序列的氨基酸序列的多肽 ID NO:7作为内部部分氨基酸序列; 包含具有SEQ ID NO:4的核苷酸序列的核苷酸序列,与SEQ ID NO:4的核苷酸序列具有至少75%同源性且含有SEQ ID NO:4的核苷酸序列的核苷酸序列的DNA 在5'末端的ID NO:8或其互补核苷酸序列; 与多肽发生免疫反应的抗体; 和检测多肽的方法。
摘要:
Disclosed are novel muteins of IL-1 compounds which can be used to regulate excess IL-1 produced in various diseases in humans and animals. The IL-1 muteins can be prepared by site-directed mutagenesis whereby a positively charged residue is replaced with a negatively charged or neutral residue at a designated position in the molecule. The resulting IL-1 muteins have reduced biological activity but retain receptor binding affinity.
摘要:
Structural analogues of fibroblast growth factors have an amino acid sequence replacement in the ninth or tenth beta strand of the factor, or the sequence that corresponds to the surface loop that connects the ninth and tenth beta strands, such that the folding of the molecule is not significantly perturbed. Preferred analogues have the overall secondary and tertiary structure of the original factor, and bind to heparin and a member or members of the fibroblast growth factor receptor family with high affinity. In some embodiments the replacement is with another amino acid sequence such as a loop sequence from another structurally related fibroblast growth factor or an interleukin. The figure discloses amino acid sequences from FGF-1, FGF-2, and IL-1 beta.
摘要:
This invention provides an antitumor active substance GIF, a process for preparing the same, an antitumor composition containing the substance, a gene coding for GIF, a vector containing the gene and a recombinant microorganism, the substance GIF comprises as its component protein polypeptide A of the following primary structure. Z Ala Pro Val Arg Ser Leu Asn Cys Thr Leu Arg Asp Ser Gln Gln Lys Ser Leu Val Met Ser Gly Pro Tyr Glu Leu Lys Ala Leu His Leu Gln Gly Gln Asp Met Glu Gln Gln Val Val Phe Ser Met Ser Phe Val Gin Gly Glu Glu Ser Asn Asp Lys Ile Pro Val Ala Leu Gly Leu Lys Glu Lys Asn Leu Tyr Leu Ser X Val Leu Lys Asp Asp Lys Pro Thr Leu Gln Leu Glu Ser Val Asp Pro Lys Asn Tyr Pro Lys Lys Lys Met Glu Lys Arg Phe Val Phe Asn Lys Ile Glu Ile Asn Asn Lys Leu Glu Phe Glu Ser Ala Gln Phe Pro Asn Trp Tyr Ile Ser Thr Ser Gln Ala Glu Asn Met Pro Val Phe Leu Gly Gly Thr Lys Gly Gly Gln Asp Ile Thr Asp Phe Thr Met Gln Phe Val Ser Ser OH wherein X is Cys or Ser and Z is H or a peptide represented by the amino acid sequence Met Lys Cys Ser Phe Gln Asp Leu Asp Leu Cys Pro Leu Asp Gly Gly Ile Gln Leu Arg Ile Ser Asp His His Tyr Ser Lys Gly Phe Arg Gln Ala Ala Ser Val Val Val Ala Met Asp Lys Leu Arg Lys Met Leu Val Pro Cys Pro Gln Thr Phe Gln Glu Asn Asp Leu Ser Thr Phe Phe Pro Phe Ile Phe Glu Glu Glu Pro Ile Phe Phe Asp Thr Trp Asp Asn Glu Ala Tyr Val His Asp or a peptide having the above sequence wherein at least one amino acid is removed from the N terminal or an amino acid.